Verona Pharma PLC ADR Cash Flow Conversion Efficiency
Verona Pharma PLC ADR cash flow conversion efficiency. Based on the latest financial reports, Verona Pharma PLC ADR (VRNA) has a cash flow conversion efficiency ratio of 0.110x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.56 Million) by net assets ($278.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Verona Pharma PLC ADR (2005–2024)
Cash flow conversion efficiency of Verona Pharma PLC ADR from 2005 to 2024. This chart illustrates how Verona Pharma PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Verona Pharma PLC ADR stock price for real-time trading data and today's change.
Verona Pharma PLC ADR Cash Flow Conversion Ratio Explained
Verona Pharma PLC ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Verona Pharma PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verona Pharma PLC ADR ranked by their cash flow conversion efficiency. Also see Verona Pharma PLC ADR stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Andritz AG
VI:ANDR
|
0.044x |
|
Silicon Motion Technology Corporation
F:S9M
|
-0.034x |
|
Tingyi (Cayman Islands) Holding Corp
F:TYG
|
0.077x |
|
UGI Corporation
NYSE:UGI
|
0.046x |
|
BARRY CALLEBA. ADR 1/100
F:BCLM
|
N/A |
|
Clearwater Analytics Holdings Inc
NYSE:CWAN
|
0.009x |
|
Gigabyte Technology Co Ltd
TW:2376
|
-0.311x |
|
Engie Brasil Energia S.A.
SA:EGIE3
|
0.078x |
Annual Cash Flow Conversion Efficiency for Verona Pharma PLC ADR (2005–2024)
The table below shows the annual cash flow conversion efficiency of Verona Pharma PLC ADR from 2005 to 2024. Review VRNA free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $204.56 Million | $-122.20 Million | -0.597x | -196.53% |
| 2023-12-31 | $249.28 Million | $-50.22 Million | -0.201x | +22.44% |
| 2022-12-31 | $230.47 Million | $-59.86 Million | -0.260x | -15.61% |
| 2021-12-31 | $148.00 Million | $-33.25 Million | -0.225x | +7.86% |
| 2020-12-31 | $184.85 Million | $-45.08 Million | -0.244x | +75.58% |
| 2019-12-31 | $44.40 Million | $-44.34 Million | -0.999x | -247.03% |
| 2018-12-31 | $79.86 Million | $-22.98 Million | -0.288x | -11.07% |
| 2017-12-31 | $107.95 Million | $-27.97 Million | -0.259x | -59.81% |
| 2016-12-31 | $42.53 Million | $-6.89 Million | -0.162x | +85.74% |
| 2015-12-31 | $8.28 Million | $-9.41 Million | -1.137x | -304.82% |
| 2014-12-31 | $19.62 Million | $-5.51 Million | -0.281x | +71.73% |
| 2013-12-31 | $3.41 Million | $-3.39 Million | -0.993x | -2.41% |
| 2012-12-31 | $4.21 Million | $-4.08 Million | -0.970x | -149.67% |
| 2011-12-31 | $6.29 Million | $-2.44 Million | -0.389x | +19.22% |
| 2010-12-31 | $5.33 Million | $-2.56 Million | -0.481x | -33.08% |
| 2009-12-31 | $7.25 Million | $-2.62 Million | -0.361x | -6.93% |
| 2008-12-31 | $5.85 Million | $-1.98 Million | -0.338x | +18.99% |
| 2007-12-31 | $5.73 Million | $-2.39 Million | -0.417x | -363.37% |
| 2006-12-31 | $7.64 Million | $-687.68K | -0.090x | -4507.76% |
| 2005-12-31 | $1.68 Million | $3.44K | 0.002x | -- |
About Verona Pharma PLC ADR
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more